Payment overview · 2025
General Payments
$1,078.35
60 reported records · 17 companies
Healthcare provider profile · identity verified
James Ryan Conner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DOTHAN, AL · NPI 1386619807
Verified facts
What the public records show
CMS Open Payments records show James Ryan Conner, M.D. received $1,078.35 in general payments during 2025 across 60 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $215.09 | 19.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $170.61 | 15.8% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $133.80 | 12.4% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.65 | 7.8% | 5 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $70.50 | 6.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.04 | 6.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.44 | 5.8% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $40.16 | 3.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.15 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.92 | 3.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.13 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.01 | 2.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.65 | 2.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.86 | 2.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.79 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.30 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,078.35 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $133.80 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $131.38 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $122.60 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.49 | 5 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $70.50 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $62.44 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.23 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $34.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $11.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 253 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 106 |
| Metformin Hcl Er | Metformin Hcl | 324 | 99 |
| Omeprazole | Omeprazole | 271 | 88 |
| Montelukast Sodium | Montelukast Sodium | 261 | 79 |
| Ezetimibe | Ezetimibe | 245 | 75 |
| Losartan Potassium | Losartan Potassium | 245 | 73 |
| Gabapentin | Gabapentin | 243 | 56 |
| Tramadol Hcl | Tramadol Hcl | 243 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 68 |
| Sertraline Hcl | Sertraline Hcl | 221 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 59 |
| Meloxicam | Meloxicam | 201 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 58 |
| Irbesartan | Irbesartan | 188 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 60 |
| Ozempic | Semaglutide | 175 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 42 |
| Eliquis | Apixaban | 163 | 35 |
| Potassium Chloride | Potassium Chloride | 163 | 52 |
| Celecoxib | Celecoxib | 154 | 48 |
| Lisinopril | Lisinopril | 141 | 39 |
| Clonazepam | Clonazepam | 139 | 29 |
| Carvedilol | Carvedilol | 129 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 37 |
| Pregabalin | Pregabalin | 118 | 30 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 114 | 35 |
| Allopurinol | Allopurinol | 111 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 33 |
| Memantine Hcl | Memantine Hcl | 109 | 28 |
| Jardiance | Empagliflozin | 106 | 24 |
| Furosemide | Furosemide | 104 | 43 |
| Temazepam | Temazepam | 104 | 16 |
| Alprazolam | Alprazolam | 103 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 19 |
| Trazodone Hcl | Trazodone Hcl | 98 | 41 |
| Mounjaro | Tirzepatide | 94 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 94 | 81 |
| Simvastatin | Simvastatin | 93 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 30 |
| Metformin Hcl | Metformin Hcl | 86 | 21 |
| Eszopiclone | Eszopiclone | 77 | 15 |
| Bupropion Xl | Bupropion Hcl | 76 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 72 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 72 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 18 |
| Baclofen | Baclofen | 66 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 18 |
| Synthroid | Levothyroxine Sodium | 61 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 60 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 20 |
| Buspirone Hcl | Buspirone Hcl | 59 | 22 |
| Lorazepam | Lorazepam | 58 | 13 |
| Donepezil Hcl | Donepezil Hcl | 57 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 19 |
| Repatha Sureclick | Evolocumab | 56 | suppressed |
| Methocarbamol | Methocarbamol | 55 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 14 |
| Prednisone | Prednisone | 52 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 18 |
| Atenolol | Atenolol | 50 | 17 |
| Benazepril Hcl | Benazepril Hcl | 50 | 13 |
| Bumetanide | Bumetanide | 50 | 19 |
| Dutasteride | Dutasteride | 50 | 15 |
| Spironolactone | Spironolactone | 48 | 16 |
| Famotidine | Famotidine | 47 | 15 |
| Ondansetron Odt | Ondansetron | 47 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 15 |
| Clonidine Hcl | Clonidine Hcl | 46 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 14 |
| Topiramate | Topiramate | 45 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 38 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Finasteride | Finasteride | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 17 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 41 | 11 |
| Glimepiride | Glimepiride | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Nifedipine Er | Nifedipine | 38 | 16 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | 11 |
| Estradiol | Estradiol | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Ramipril | Ramipril | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Nitroglycerin | Nitroglycerin | 22 | 19 |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 16 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Belsomra | Suvorexant | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,078.35 · 60 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, INGREZZA, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QUTENZA, REPATHA, REXULTI, SYMPLICITY G3, The Cologuard Plus Collection Kit, VERQUVO, VYNDAQEL, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error